Corpus Intelligence IC Memo — BRENTWOOD SPRINGS 2026-04-26 15:12 UTC
IC Memo — BRENTWOOD SPRINGS
Investment Committee Memorandum | IN | 48 beds | Grade C | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BRENTWOOD SPRINGS

CCN 154055 | nan, IN | 48 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BRENTWOOD SPRINGS is a 48-bed suburban community hospital in nan, IN with $16.3M in net patient revenue and a 4.5% operating margin. The hospital serves a payer mix of 5.2% Medicare, 3.4% Medicaid, and 91.4% commercial.

Thesis: Turnaround. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 4.5% to 11.9% (+736bps).

Net Revenue HCRIS$16.3M
Current EBITDA COMPUTED$734K
Operating Margin COMPUTED4.5%
Occupancy HCRIS74.5%
Revenue / Bed COMPUTED$339K
Net-to-Gross HCRIS34.5%
Distress Probability ML43.0%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
90
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of 4.5% places it above the state median. Among 90 size-comparable peers (24-96 beds), the median margin is -1.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (24-96), prioritizing same-state peers. 90 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BRENTWOOD SPRINGS (Target)IN48$16.3M4.5%
MEMORIAL HOSP & HEALTH CARE CTIN96$259.1M28.7%
INDIANA ORTHOPAEDIC HOSPITAL LIN38$196.8M31.2%
LAPORTE HOSPITALIN74$192.4M19.3%
SCHNECK MEDICAL CENTERIN60$184.2M-0.8%
ORTHOPAEDIC HOSPT.AT PARKVIEWIN37$175.7M36.8%
LUTHERAN MUSCULOSKELETAL CENTEIN39$168.9M25.0%
WITHAM MEMORIAL HOSPITALIN50$158.5M-11.6%
FRANCISCAN HEALTH MOORESVILLEIN80$157.3M26.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$341K+210bp18mo
Cost to Collect4.5%2.5%$325K+200bp12mo
Denial Rate Reduction12.0%6.5%$322K+198bp12mo
A/R Days Reduction5200.0%3800.0%$198K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$341K
Cost to Collect
$325K
Denial Rate Reduction
$322K
A/R Days Reduction
$198K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.2M
Current EBITDA$734K
+ RCM Uplift+$1.2M
Pro Forma EBITDA$1.9M
Current Margin4.5%
Pro Forma Margin11.9%
WC Released (1x)$623K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.1M$16.8M14.88x71.6%
Base (11x exit)10.0x11.0x$1.1M$18.9M16.69x75.6%
Bull Case9.0x11.0x$1.0M$23.2M22.78x86.9%
Bull (12x exit)9.0x12.0x$1.0M$25.6M25.15x90.6%
Bear Case11.0x10.0x$1.2M$10.5M8.42x53.1%
Bear (11x exit)11.0x11.0x$1.2M$11.9M9.58x57.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 90 hospitals with 24-96 beds
  • Same-state prioritization (n=91)
  • Comp margins: P25=-11.7% / P50=-1.7% / P75=9.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.